Stryker Q4 2024 Earnings Report
Key Takeaways
Stryker reported a 10.7% increase in net sales to $6.4 billion, with organic net sales up 10.2%. Adjusted EPS increased by 15.9% to $4.01, while reported EPS decreased 52.7% to $1.41 due to non-cash charges for goodwill and other impairments. The company anticipates organic net sales growth of 8.0% to 9.0% for 2025 and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.
Net sales increased by 10.7% to $6.4 billion.
Organic net sales increased by 10.2%.
Adjusted EPS increased by 15.9% to $4.01.
Reported EPS decreased 52.7% to $1.41, impacted by goodwill and other impairments.
Stryker
Stryker
Stryker Revenue by Geographic Location
Forward Guidance
Stryker anticipates organic net sales growth of 8.0% to 9.0% for 2025 and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.
Positive Outlook
- Momentum exiting 2024
- Sustained level of procedural volumes
- Strong demand for capital products
- Presence in healthy end markets
- Full year impact of price on sales will be modestly favorable
Challenges Ahead
- Full year net sales will be unfavorably impacted by approximately 1% due to foreign exchange rates
- Adjusted net earnings per diluted share will be negatively impacted by approximately $0.10 to $0.15 due to foreign exchange rates
- Inari is expected to deliver approximately $590 million of sales in the 2025 stub period on a constant currency basis
- Inari will have dilutive impacts on adjusted operating income margin of 0 to 20 basis points
- Inari will have dilutive impacts on adjusted net earnings per diluted share of $0.20 to $0.30
Revenue & Expenses
Visualization of income flow from segment revenue to net income